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RESEARCH ARTICLE
In Vivo Imaging Reveals Rapid Astrocyte
Depletion and Axon Damage in a Model
of Neuromyelitis Optica-Related
Pathology
Marina Herwerth, MD,1,2,3 Sudhakar Reddy Kalluri, MSc,1
Rajneesh Srivastava, MSc,1 Tatjana Kleele, PhD,2 Selin Kenet, MSc,2
Zsolt Illes, MD, PhD,4,5 Doron Merkler, MD,6,7,8 Jeffrey L. Bennett, MD, PhD,9
Thomas Misgeld, MD,2,3,10,11,12 and Bernhard Hemmer, MD1,3,12
Objective: Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system, which resembles
multiple sclerosis (MS). NMO differs from MS, however, in the distribution and histology of neuroinflammatory
lesions and shows a more aggressive clinical course. Moreover, the majority of NMO patients carry immunoglobulin
G autoantibodies against aquaporin-4 (AQP4), an astrocytic water channel. Antibodies against AQP4 can damage
astrocytes by complement, but NMO histopathology also shows demyelination, and— importantly—axon injury,
which may determine permanent deficits following NMO relapses. The dynamics of astrocyte injury in NMO and the
mechanisms by which toxicity spreads to axons are not understood.
Methods: Here, we establish in vivo imaging of the spinal cord, one of the main sites of NMO pathology, as a power-
ful tool to study the formation of experimental NMO-related lesions caused by human AQP4 antibodies in mice.
Results: We found that human AQP4 antibodies caused acute astrocyte depletion with initial oligodendrocyte survival.
Within 2 hours of antibody application, we observed secondary axon injury in the form of progressive swellings. Astro-
cyte toxicity and axon damage were dependent on AQP4 antibody titer and complement, specifically C1q.
Interpretation: In vivo imaging of the spinal cord reveals the swift development of NMO-related acute axon injury
after AQP4 antibody-mediated astrocyte depletion. This approach will be useful in studying the mechanisms underlying
the spread of NMO pathology beyond astrocytes, as well as in evaluating potential neuroprotective interventions.
ANN NEUROL 2016;79:794–805
Axon damage is a common phenomenon in manyneurological diseases, including those of neuroim-
munological origin.1 Indeed, in multiple sclerosis (MS),
the degree of axon damage is an important determinant
of chronic disability.2,3 However, because the pathological
cascades that drive axon damage in MS are not known,
only limited understanding of the mechanisms underly-
ing this important aspect of pathology has been possible.
In contrast, in neuromyelitis optica (NMO), an auto-
immune disease that mainly affects the optic nerve and
spinal cord,4 the autoimmune target has been identified
in the majority of patients. Most NMO patients have a
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specific serum antibody response to aquaporin-4
(AQP4),5–8 a water channel, which in the central nervous
system (CNS) is expressed on astrocytes, especially on
perivascular and superficial glia limitans processes. Anti-
bodies to AQP4 (AQP4-Ig [immunoglobulin]) are also
present in the cerebrospinal fluid (CSF) of NMO
patients, although at a lower titer.8–10 Occurrence of
AQP4-Ig in serum and CSF, loss of astrocytes, deposition
of complement, and infiltration of macrophages in
NMO lesions together imply a specific immune response
against AQP4-expressing astrocytes.11–13 Indeed, intra-
peritoneal injection of NMO serum immunoglobulins
containing AQP4-Ig or of AQP4-specific recombinant
antibodies combined with opening of the blood–brain
barrier (BBB) by T-cell-mediated inflammation or intra-
cerebral needle injury can produce astrocyte loss and
demyelination in rats.9,13–15 Similarly, injection of
AQP4-Ig and human complement into mouse brain
induces NMO-like lesions.16 The majority of AQP4-Ig
belongs to the IgG1 subclass, which can activate the com-
plement cascade upon target binding,8 and hence the
presence of complement and antibody effector function
is essential in transfer models that show astrocyte loss. In
line with these observations, plasma exchange, which
reduces circulating IgG and complement levels, is effec-
tive in treating NMO relapses.17 In addition to astrocyte
loss and immunopathology, demyelination and axon
damage have been identified histologically in NMO.18,19
Although demyelination has been investigated in some
detail in previously reported animal models, the impact
of AQP4-Ig-mediated astrocyte loss on axons has
received less attention.9,13–16 This is despite the fact that
axon damage appears to be an early feature of human
pathology19 and likely underlies some of the residual def-
icits after NMO relapses. Thus, improved models to
study the mechanisms by which AQP4-Ig-induced dam-
age spreads from astrocytes to axons are needed.
Here, we use an in vivo two-photon imaging
approach to the mouse spinal cord that we previously
established20–22 to gain insight into AQP4-Ig-mediated
lesion formation. We found that AQP4-Ig-containing
samples obtained from NMO patients (as well as a
recombinant AQP4-IgG from a clonotypic plasma blast
present in the CSF of an NMO patient) caused acute,
dose-dependent and (human) complement-mediated loss
of astrocytes when applied at the pial surface of the spi-
nal cord at IgG concentrations found intrathecally in
NMO.23 Using combinatorial transgenic labeling of dif-
ferent CNS cell types, we revealed secondary axon dam-
age, which, in onset and extent, correlated with astrocyte
loss and AQP4-IgG titer. This imaging approach will
provide a novel way to study, in real time and with
single-cell resolution, how secondary damage emerges




We used 2- to 4-month-old transgenic male and female mice to
visualize astrocytes (Aldh1l1:GFP; obtained from MMRRC:
strain Tg(Aldh1l1-EGFP)OFC789Gsat/Mmucd24) and axonal
morphology (Thy1:OFP25 courtesy of Jeff Lichtman, Harvard
University, Cambridge, MA) for in vivo experiments and 3- to
5-week-old Aldh1h1:GFP mice for ex vivo experiments. In
some experiments 2- to 4-month-old C57BL/6 mice were used
as transgene-free controls. Plp:CreER3ROSA:STOP-TdTomato
mice (Ai14; The Jackson Laboratory, Bar Harbor, ME)26,27, in
which oligodendrocytes are labeled, were used to control for
cell-type specificity (tamoxifen injection proved unnecessary
because of constitutive activity of the CreER in adult animals).
Tissue samples from AQP4 knockout mice were obtained from
Alan Verkman (University of California San Francisco, San
Francisco, CA).28 Animal experiments were conducted in
accord with local regulations and were approved by the respon-
sible regulatory agencies.
Patients, Serum/Plasma Samples, and
Complement Sources
NMO patients were recruited from the Department of Neurol-
ogy, University of Pecs, (Pecs, Hungary) and from the Depart-
ment of Neurology, Klinikum rechts der Isar, Technical
University of Munich (Munich, Germany). All patients were
examined by neurologists specialized in neuroimmunology and
fulfilled the diagnostic criteria for NMO based on Winger-
chuk’s criteria.4 Serum or plasma samples of 4 AQP4-Ig-
positive individuals were included in this study, 3 of which
(referred to as NMO1-3 below) were used in in vivo experi-
ments. As controls, samples of 3 healthy subjects (ctrl1-3,
below), without signs of an autoimmune disease or infection at
the time of blood sampling, were included in cooperation with
the blood bank of the Bavarian Red Cross. Blood samples were
collected by venipuncture, centrifuged at 3,000rpm for 10
minutes, split into aliquots, frozen for storage at –80 8C, and
thawed only on the day of the experiment. All blood samples
were tested for being human immunodeficiency virus, hepatitis
B virus, and hepatitis C virus negative. All subjects gave written
informed consent to the use of their blood samples for research.
Moreover, for complement depletion and reconstitution assays,
we obtained human C1q-depleted sera and purified C1q com-
ponent from Merck Millipore (Billerica, MA).
Acute Brain Slice Preparation
Ex vivo acute brain slice experiments were performed as previ-
ously described.29 In brief, brains from Aldh1l1:GFP mice were
removed, cut centrally into coronal slices (300mm) in Ringer’s/
artificial cerebrospinal fluid (aCSF; pH7.4 at 4 8C) containing
(in mM): 125 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2
CaCl2, 1 MgCl2, and 20 glucose, followed by recovery at 35 8C
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for 1 hour. Slices were transferred to a recording chamber and
continuously superfused with 50ml of recirculating, heated
(30 8C), and oxygenated (95% O2/5% CO2) aCSF (1.5–2.0ml/
min). After complement inactivation at 56 8C for 30 minutes,
we applied diluted NMO or control sera/plasma (IgG levels
adjusted to the values indicated in the figures), together with
4% non-heat-inactivated serum from healthy donors (HDs) as
a source of complement (referred to as HD serum below),
which remained in the aCSF from 0 to 180 minutes of the
experiment. Image stacks (30 images, 2-mm z-spacing) were
acquired using a two-photon microscope (Olympus FV1000
MPE tuned to 910 nm, equipped with a 325/1.05 numerical
aperture [N.A.] water dipping cone objective; Olympus, Tokyo,
Japan) at 3-minute intervals for 3 hours.
Surgical Procedures and In Vivo Imaging
Laminectomy surgeries were performed as previously
described21: Mice were anesthetized by an intraperitoneal injec-
tion of ketamine-xylazine (87mg/kg/13mg/kg, respectively) or
meditomidin 0.5mg/kg, midazolam 5mg/kg, and fentanyl
0.05mg/kg. Anesthesia was reapplied as needed (every 60–120
minutes). After a double dorsal laminectomy over the fourth
lumbar, L4, and L5 segments, mice were suspended using com-
pact spinal cord clamps.30 A well around the opening was built
using 2-4% agarose to hold aCSF (as above, glucose omitted or
alternatively, in mM: 148.2 NaCl, 3.0 KCl, 0.8 Na2HPO4, 0.2
NaH2PO4, 1.4 CaCl2, and 0.8 MgCl2). An imaging window
free from dura was established in the imaging area using a bent
hypodermic needle. In some experiments, astrocyte death was
verified by addition of ethidium homodimer-1 (1:500, 0.56mg/
ml stock; Invitrogen, Carlsbad, CA).
In vivo imaging of the lumbar spinal cord was performed
as previously described.21,31 Briefly, stacks were acquired using
two-photon microscopes (Olympus FV1000 MPE or FVMPE-
RS tuned to 910 nm for green fluorescent protein [GFP] alone
and 980nm for GFP/OFP [orange fluorescent protein],
equipped with a 325/1.05N.A. water-dipping cone objective).
All light was first filtered through a 690 nm short-pass dichroic
mirror. Fluorescence was collected using a G/R filter set (BA
495-540, BA 570-625) mounted in front of gallium arsenide
phosphide photomultiplier tubes. Time-lapse stacks were
acquired at 3-minute intervals for 3 hours (astrocyte loss) or at
15-minute intervals for 6 hours (axon damage) with the follow-
ing parameters: 35 images (zoom 1.8–2.0; pixel size: 0.28–
0.38mm) with 1-mm z-step. Diluted heat-inactivated serum/
plasma was applied every 30 minutes, supplemented with 20%
of non-heat-inactivated HD serum as a complement source.
Compared to experiments with acute brain slices, a higher con-
centration was needed, most likely because of restricted penetra-
tion and possibly the presence of complement blockers in vivo.
Serum/plasma was present in the spinal opening for the initial
90 minutes of the experiment, after which it was replaced with
aCSF (at 90 minutes and renewed every 60 minutes until the
end of the experiment). Transient delivery of the NMO sample
and complement source was designed to induce an acute, well-
defined injury and reduce consumption of sparse patient-
samples. In a set of control experiments using NMO1 samples
and HD serum for up to 8 hours continuously, we found no
qualitative difference between prolonged and transient applica-
tions, although, as expected, astrocyte depletion and the degree
of axon swellings was more pronounced after longer exposure
to patient IgG and complement. To confirm AQP4 specificity,
we also performed experiments using a human IgG1 recombi-
nant antibody rAb 7-5-53 reconstructed from a clonotypic
plasma blast obtained from the CSF of an NMO patient (r-
AQP4-IgG)9. r-AQP4-IgG was applied at 1.5lg/ml of IgG
supplemented with 20% of non-heat-inactivated HD serum.
The rAb ICOS-5-2, a divalent human IgG1 antibody of
unknown specificity, developed from a chronic meningitis
patient, served as an isotype control (r-ctrl-IgG).
We have previously demonstrated that phototoxicity does
not appear to have a measurable impact on the health of spinal
axons under such imaging conditions.21,22,31,32 Moreover, histo-
logical analysis confirmed NMO serum-/plasma-mediated astro-
cyte loss in the absence of oligodendrocyte loss in superficial
spinal cord layers when no imaging was done (see below and cf.
Fig 1G,H). Additionally, axonal pathology could be confirmed
in experiments in which only an initial and a final image (at 6
hours) were taken (cf. Fig 4B). To rule out a spurious influence
of the transgenic labeling of axons, we performed experiments
without imaging using wild-type (C57BL/6) and transgenic ani-
mals and antitubulin staining (see below). The analysis was per-
formed by a scorer blind to the treatment conditions and
genotypes and showed a comparable percentage of axonal swel-
lings in spinal cords treated with NMO serum/plasma irrespec-
tive of genotype (data not shown).
Immunohistochemistry and Histological Analysis
After transcardiac perfusion with 4% paraformaldehyde (PFA)
in 0.01M of phosphate-buffered saline (13PBS; in mM: 1.5
KH2PO4, 2.7 KCl, 8.1 Na2HPO4, and 137 NaCl), the spinal
cord and brain from Adh1l1:GFP mice were postfixed for 24
hours in 4% PFA, then dissected and put in sucrose (30%)
solution for a further 12 to 24 hours. Subsequently, 20-mm-
thick cryosections were cut in a cryostat. For staining, NMO1
plasma or serum (and control sera from healthy donors) was
used at 1:1,000 in 0.2% Triton X-100, 10% normal goat
serum, and 1% bovine serum albumin in 13PBS (followed by
incubation with appropriate secondary antibodies; antihuman
IgG 1:200, ABC-complex, streptavidin Alexa Fluor 555
1:1,000). Glial fibrillary acidic protein (GFAP) antibody (rat;
Invitrogen) was used at a concentration of 1:200 (followed by
goat Alexa Fluor 647–conjugated antirat IgG 1:1,000). Sections
were mounted in 40,6-diamidino-2-phenylindole (DAPI)-con-
taining mounting medium, and image stacks were recorded on
a confocal microscope (Olympus FV1000) equipped with3 20/
0.8N.A. and 360/1.42N.A. oil-immersion objectives. For
tubulin stainings, we used an Alexa Fluor 647–conjugated anti-
body to tubulin III beta (mouse; BioLegend) at 1:200 and
stained spinal cord whole mounts22 of wild-type control
(C57BL/6) or Thy1:OFP mice that were either treated with
NMO or control samples plus HD serum for 6 hours without
ANNALS of Neurology
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imaging. Confocal images were taken as described above for
GFAP stainings. To control for effects of imaging and transgene
expression on astrocyte loss, we performed dorsal laminectomy
surgery on wild-type control (C57BL/6) and Aldh1l1:GFP mice
as described for imaging above. We applied heat-inactivated
NMO, as well as control samples with HD serum as a comple-
ment source as detailed above, but no imaging was performed.
Instead, after 3 hours, animals were perfused, their spinal cords
embedded in paraffin, and subjected to histopathological analy-
sis according to standardized protocols as described previously.33
Briefly, immunostaining was performed using the following pri-
mary antibodies: rabbit/anti-GFAP (astrocytes; 1:2,000; code
no.: Z0334; Dako, Carpinteria, CA) and mouse/anti-NogoA
(mAb11C7, 1:20,000; kindly provided by M.E. Schwab, Zur-
ich, Switzerland). Bound primary antibodies were visualized
using a ready-to-use, peroxidase-based secondary detection sys-
tem (EnVision; Dako) with 3,30-diaminobenzidine as chromo-
gen (hemalaun counterstaining of nuclei). Immunostained
sections were scanned using a Panoramic Digital Slide Scanner
250 FLASH II (3DHISTECH Ltd., Budapest, Hungary) at
2003magnification. Astrocyte and oligodendrocyte densities in
the superficial dorsal spinal cord (<50lm from pial surface)
were counted manually using Panoramic Viewer software
(3DHISTECH Ltd.) by a scorer blind to the treatment condi-
tions and genotypes.
FIGURE 1: NMO patient-derived samples contain AQP4-Ig
that stains and ablates mouse astrocytes in vitro and in
vivo. (A) White matter spinal cord cryosections of
Aldh1l1:GFP mice (Aldh:GFP, left; GFP not shown) and
AQP4-knockout-mice (AQP4–/–, right), stained for astrocytes
(GFAP, green), nuclei (DAPI, white), and with an AQP4-Ig-
containing NMO sample (NMO1, red). (B) Confocal image of
a fixed brain slice from an Aldh1l1-GFP mouse. Box indi-
cates the relative size of a typical time-lapse area as magni-
fied in (C). (C) Two-photon image of astrocytes in an acute
brain slice. Boxed area time-lapsed in (D), left column. (D)
Time-lapse images taken from acute brain slices every 3
minutes for 3 hours, showing astrocytes (red arrowheads)
that lose fluorescence and die in the presence of a heat-
inactivated AQP4-Ig-containing NMO sample (NMO1) and
HD serum as a source of complement. A control serum
(ctrl1) had no detectable effect under the same conditions.
(E) Astrocyte survival over 180 minutes in acute brain slices
in the presence of control sera from healthy subjects (ctrl1-
3) and an AQP4-Ig-containing NMO serum (NMO1, 300lg/
ml of IgG; n53 recordings for each sample; p<0.0001, log-
rank test). (F) Dose-response curve of astrocyte survival
after 180 minutes for an AQP4-IgG containing NMO
(NMO1) and three control samples (n53 recordings for
each sample; p50.0045, Mann–Whitney U test, NMO1 vs
pooled ctrl1-3 for 300-lg/ml IgG concentration). HD serum
(4%) as a source of complement was present in all record-
ings in (E) and (F). (G and H) Histopathological quantification
of astrocyte (GFAP; G) and oligodendrocyte (Nogo-A; H)
densities in the superficial spinal cord of wild-type and
Aldh1l1:GFP mice after 180-minute in vivo application of
heat-inactivated AQP4-Ig-containing NMO (NMO1) or a con-
trol sample (ctrl1) supplemented with HD serum into a lami-
nectomy opening (n53 mice for each genotype/treatment
combination; GFAP: wild-type ctrl1 vs NMO1 p<0.001;
Aldh:GFP ctrl1 vs NMO1 p<0.01; Nogo-A: no significant dif-
ferences, D’Agostino and Pearson’s normality test, followed
by analysis of variance and Holm-Sidak’s multiple compari-
sons test). Scale bars, 10mm in (A), 500mm in (B), 20mm in
(C), and 10mm in (D). Data are presented as mean6 standard
error of the mean. AQP45 aquaporin-4; DAPI540,6-diami-
dino-2-phenylindole; GFAP5glial fibrillary acidic protein;
GFP5green fluorescent protein; HD5healthy donor;
Ig5 immunoglobulin; NMO5neuromyelitis optica.
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AQP4-Specific Immunoglobulin Depletion From
Patient Samples
HEK293 cells (2*109) expressing C-terminally His-tagged
AQP4 were lysed in 5ml of nondenaturing base lysis buffer (in
mM: NaCl 300, Tris-HCl [pH7.4] 10, phosphate buffer
[pH 7.4] 50, imidazol [pH 7.4] 10, 200ml of ethylenedimaine-
tetraacetic acid [EDTA]-free protease inhibitor cocktail, and
5 ml of benzoase) with 1% decyl b-D-maltopyranoside for 40
minutes at room temperature. Lysate was centrifuged at
50,000g and cleared supernatant incubated with 500ml of pre-
equilibrated HisPur Cobalt Resin (Life Technologies, Carlsbad,
CA) for 1 hours. The resin was spun down and washed thor-
oughly with washing buffer I (as above, but containing only
0.01% decyl b-D-maltopyranoside) multiple times until absorp-
tion at 280nm became undetectable. Resin was resuspended in
40ml of 0.03% H2O2 and agitated at room temperature for 2
hours for oxidation of Co(II) to Co(III), spun down, and
washed with wash buffer II (PBS and 100mM of EDTA) to
strip away any unoxidized divalent ions.34 This AQP4 resin was
used to deplete antigen-specific Ig from samples. Control col-
umns were prepared in the same way, however, using sham-
transfected HEK293 cells. For access to sufficient volumes,
AQP4-specific Ig depletion experiments were performed with
NMO1 plasma.
AQP4-Antibody Titration Assay
Sera and recombinant Abs were measured at different dilutions
using a cell-based flow cytometry assay. The human glioblas-
toma cell line, LN18, was stably transduced using a lentiviral
vector to overexpress human AQP4-M23 as previously reported
(LN18AQP4).8,9 Results were expressed as median fluorescence
FIGURE 2: Human AQP4-Ig samples induce rapid astrocyte
pathology in the murine spinal cord in vivo. (A) Schematic
sketch of the setup of the in vivo imaging experiment. Note
that NMO and control samples were exchanged three times
and replaced by aCSF after 90 minutes. (B) Overview of a
typical imaging area in Aldh1l1:GFP mice (GFP, green)
before application of NMO samples. Boxed area is followed
by time lapse in (C), left column. (C) In vivo time-lapse series
of astrocytes (GFP, green) that lose fluorescence and die
(red arrows) in the presence of a heat-inactivated AQP4-Ig-
containing NMO sample (NMO1) plus HD serum as comple-
ment source. Control serum (ctrl2) does not affect astro-
cytes under the same conditions. Bottom panel shows
uptake of the cell death marker, ethidium homodimer (red),
which was present during the in vivo recording, in astro-
cytes that lost fluorescence in response to AQP4-Ig-
containing serum (boxed area is magnified to the right).
(D) Percentage of surviving astrocytes in the presence (0–90
minutes) of control (ctrl) and AQP4-Ig-containing NMO sam-
ples (NMO) with HD serum as complement source (n53–5
recordings per sample; p<0.001, for NMO1-3 each tested
vs ctrl1, log-rank test; adjusted to 150lg/ml for NMO and
300lg/ml for ctrl samples). (E) Dose response of astrocyte
loss as a function of total IgG concentration after 120
minutes for one NMO and several control samples (n53–5
recordings per sample, 100–300lg/ml; n51–2 recordings
for 0–75lg/ml). All samples were complemented with the
same amount of HD serum (p50.0045, for NMO1 vs
pooled ctrl1-3 for 300-lg/ml concentration, Mann–Whitney
U test). Scale bars, 20 mm in (B), 10mm in (C). Data are pre-
sented as mean6 standard error of the mean. aCSF5 artifi-
cial cerebrospinal fluid; AQP45 aquaporin-4; GFAP5glial
fibrillary acidic protein; GFP5green fluorescent
protein; HD5healthy donor; Ig5 immunoglobulin; NMO5
neuromyelitis optica.
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intensities (MFI) corrected for background binding to a cell
line that was transduced with an empty vector (LN18CTR).
Samples were considered to be positive if the DMFI value was
above 50 (where DMFI is the MFI difference between
LN18AQP4 and LN18CTR, and a measure of the concentration
of AQP4-specific IgG).
Image Processing and Data Analysis
Images were processed using the open-source image analysis
software, Fiji35 and Adobe Creative Suite. Gamma was adjusted
linearly in all figure panels; gamma was adjusted nonlinearly in
video files to enhance visibility of morphological detail. Percent-
age of cell loss was defined as percentage of cells that lost
>50% of their fluorescence, which was accompanied by clear
FIGURE 3: NMO-related astrocyte pathology is AQP4-Ig specific and complement dependent. (A) Titration of the NMO
patient-derived sera and control sera in an in vitro binding assay. Antibody titers in serum correspond to the difference in
binding to an AQP4-transduced cell line and a control cell line (delta median fluorescence intensity; DMFI). (B) Correlation
between the AQP4-Ig titer and the time when 50% astrocyte loss was reached (t50; 150mg/ml). Mean values are presented as
green data symbols. (C) Complement inactivation (complement –) or AQP4-Ig depletion by an AQP4-preabsorption column
(AQP4 Ig–) abolishes the pathological effects on astrocytes caused by the AQP4-Ig-containing NMO1 sample. A preabsorption
column without AQP4-antigen has no effect (AQP4 IgG1; n52–5 for all conditions; p<0.0001, log-rank test). (D) C1q factor
depletion (C1q neg serum1/C1q–) abolishes the pathological effects on astrocytes caused by the NMO1 sample. Resubstitu-
tion of purified C1q factor (20mg/ml) reinstates the effect (C1q neg serum1/C1q1), whereas C1q alone has no effect (C1q neg
serum–/C1q1; n53 for all conditions; p<0.0001, log-rank test). (E) Titration as in (A) of a recombinant AQP4 antibody (r-
AQP4-IgG) and of a control antibody (r-ctrl-IgG). (F) Percent of surviving astrocytes in the presence of r-AQP4-IgG and r-ctrl-
IgG (1.5 mg/ml; n3 recordings for all conditions, p<0.0001, log-rank test). Data are presented as mean6 standard error of
the mean. AQP45aquaporin-4; HD5healthy donor; Ig5 immunoglobulin; NMO5neuromyelitis optica.
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changes in morphology (rounding, process blebbing). Axon
morphology in a neuroinflammatory setting was staged as
described previously.21,22 Only axons that were observable
across all time points during the experiment over at least 50mm
were analyzed. Each axonal swelling was verified by observa-
tions of morphology within unprocessed three-dimensional
(3D) image stacks. We relinquished scoring the morphological
changes of astrocytes and axons blindly, given that the differ-
ence between control and NMO experiments was obvious.
Data sets were processed with Excel (Microsoft Corporation,
Redmond, WA). For survival curves (Figs 1E, 2D, 3F, and
4C,G), a custom-written Python script was used for analysis.
Statistical Analyses
The proportion of surviving astrocytes and of axons with swel-
lings was analyzed with Kaplan-Meier estimates, and treatment
differences were compared with log-rank test. For control
experiments (axon damage without time lapse), we used non-
parametric tests. For comparison of two conditions, we used
the Mann–Whitney U test; for comparison of more than two
conditions, we used Kruskal-Wallis’ followed by Dunn’s multi-
ple comparison test. For histopathology, normal distribution of
values obtained from individual analyzed fields of view was
confirmed using D’Agostino and Pearson’s normality test, fol-
lowed by analysis of variance and Holm-Sidak’s multiple com-
parisons test. Data are shown as mean6 standard error of the
mean (SEM); significance statements are included in the figure
legends.
Results
NMO Patient-Derived AQP4 Antibodies Induce
Acute Astrocyte Pathology Ex Vivo
As a first step toward establishing an in vivo assay for
NMO-related neuropathology, we used isolated mouse
brain tissue to (1) confirm that human AQP4-Ig can
bind and damage mouse astrocytes, as shown previously
in slice cultures,36 (2) define the time course, concentra-
tion ranges, and complement requirements that charac-
terize these effects, and (3) devise a transgene-based
readout of astrocyte death, taking advantage of astrocyte-
FIGURE 4: AQP4-antibody mediated astrocyte loss is fol-
lowed by axonal pathology in vivo. (A) Time-lapse imaging of
the spinal cord in vivo (every 15 minutes for 6 hours) reveals
axons that develop progressive swellings in the presence of
an AQP4-Ig-containing sample (NMO2), whereas in the pres-
ence of a control sample (ctrl3), axons remain unaffected. (B)
The same experiment as in (A), but without two-photon
imaging. Afterward, the tissue was fixed and images of the
spinal cord were taken on a confocal microscope (axons,
magenta; astrocytes, green) and quantitatively compared to
imaged samples (same data as in C), as shown in the graph
on the right (n53; p50.7, Mann–Whitney U test). (C) Per-
centage of swollen axons as a function of time using three
different NMO patient-derived AQP4-Ig-containing samples
(NMO1-3; 150lg/ml) vs three control samples (ctrl1-3;
300lg/ml, n>120 axons from three experiments for each
sample; p<0.0001, log-rank test of NMO1-3 individually vs
ctrl1). (D) Example of concomitant quantification of astrocyte
survival (green) and axonal swellings (magenta) in one
recording using sample NMO2 complemented with HD
serum, which were present from 0 to 90 minutes. (E) Correla-
tion between survival of astrocytes and axonal swellings after
6 hours induced by the indicated AQP4-Ig-containing sam-
ples. Mean values are presented as magenta data symbols.
(F) Analogous to Figure 3C, complement inactivation and
AQP4-Ig depletion abolish the pathological effects of
NMO patient-derived samples on axons (n52–3 for each
condition; p<0.0001, log-rank test; 360 minutes). (G) Per-
centage of astrocyte survival (green) and axonal swellings
(magenta) in the presence of the recombinant AQP4-
antibody (‘r-AQP4-IgG’; 1.5mg/ml, n>125 axons, n53;
p<0.0001 compared to r-ctrl-IgG, data not shown, log-rank
test). Scale bars, 10mm in A and B. Data are presented as
mean6 standard error of the mean. AQP45 aquaporin-4;
HD5healthy donor; Ig5 immunoglobulin; NMO5
neuromyelitis optica; OFP5orange fluorescent protein.
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specific GFP expression in Aldh1l1:GFP mice.24 First, we
confirmed that our AQP4-Ig-containing NMO samples
specifically labeled GFAP-positive astrocytes in mouse
spinal cord white matter. This staining was absent on tis-
sue of AQP4-knockout mice (Fig 1A) and when we used
AQP4-Ig-negative serum samples (data not shown). Sec-
ond, we applied diluted, heat-inactivated, AQP4-Ig-posi-
tive NMO (or AQP4-Ig-negative control) samples
together with a complement source (non-heat-inactivated
HD serum) to acute brain slices from Aldh1l1:GFP
mice. Within 60 minutes, we observed swelling and frag-
mentation of astrocyte processes, as well as rounding of
cell somata, followed by loss of fluorescence (Fig 1B–D,
Supplementary Video 1). The degree of astrocyte loss
was dose dependent and patient specific (survival of
astrocytes after 180 minutes as mean percentage6 SEM,
average of 3 experiments each: 42.16 5.8 and
63.96 7.3 for two different AQP4-Ig-positive NMO
samples, one of which [NMO1] is illustrated in Fig
1E,F). In contrast, control sera had no effects over our
observation period of 3 hours (100.06 0.0,
99.46 0.6,and 99.66 0.4 for three control sera and
three repeats each)—moreover, in subsequent experi-
ments, we found the toxic effects of these NMO samples
to be specifically mediated by AQP4-Ig and the classical
complement cascade (see below). Together, these experi-
ments confirmed the notion that NMO patient-derived
AQP4-Ig induce astrocyte pathology, which we could fol-
low dynamically using Aldh1l1:GFP mice.
Human AQP4 Antibodies Exert Acute
Pathological Effects in Mouse Spinal Cord
In Vivo
To establish an in vivo model of NMO-related astrocyte
toxicity, we first confirmed that a quasi-intrathecal route
of application (application into a laminectomy with dura
removal) would suffice to induce astrocyte pathology. We
chose this approach because it is compatible with the in
vivo imaging technique we sought to employ, which
depends on a surgical exposure of the dorsal spinal cord,
but also because NMO patients can harbor substantial
amounts of AQP4-Ig in their CSF (as well as plasma
blasts that secrete such antibodies).8–10,23 To determine
astrocyte pathology in this setting, we performed stand-
ard histopathological analysis after a 3-hour treatment
with an AQP4-Ig-positive NMO sample plus HD serum
applied to a laminectomy. We found a clear reduction in
GFAP staining in the superficial spinal cord. At the same
time, an oligodendrocyte marker remained unchanged,
confirming astrocyte-specific toxicity of AQP4-Ig-
containing NMO samples in the presence of complement
(Fig 1G,H) as shown previously for intraparenchymal
injections.16
Next, we took advantage of a two-photon imaging
approach to visualize cells in the dorsal spinal cord of
anesthetized mice.21,32 After establishing a spinal cord
imaging window in Aldh1l1:GFP mice, we applied heat-
inactivated AQP4-Ig-positive NMO samples (n5 3;
NMO1 to NMO3) together with untreated HD serum
as a source of complement from 0 to 90 minutes (after
which antibodies and complement were replaced by
aCSF; the same HD serum at a fixed concentration of
20% was used in all in vivo experiments). This allowed
us to follow AQP4-Ig-mediated astrocyte toxicity over
several hours (Fig 2A). In line with our ex vivo observa-
tions, we found that NMO patient-derived AQP4-Ig-
containing samples caused swelling and fragmentation of
astrocytes in vivo, followed by loss of fluorescence, which
correlated with uptake of the cell-death marker dye, ethi-
dium homodimer (Fig 2B,C; Supplementary Video 2).
Astrocyte damage was dose dependent and correlated
with the AQP4-Ig titer measured in an in vitro binding
assay (Figs 2D,E and 3A,B; mean survival of astrocy-
tes6 SEM after 120 minutes at 150 lg/ml in %: NMO1
23.06 8.6, n5 5; NMO2 9.76 4.7, n5 4; NMO3
62.96 7.3, n5 5; t50 in min: NMO1 65.16 4.5;
NMO2 52.36 7.4; NMO3 89.96 5.1). In the presence
of control sera with untreated HD serum astrocytes
remained unaffected even at high concentration (300 lg/
ml of IgG; mean survival of astrocytes6 SEM after 120
minutes in %: ctrl1 99.16 0.9, n5 3; ctrl2 100.06 0.0,
n5 3; ctrl3 98.56 0.8, n5 3). Moreover, for the first
hour after application, AQP4-Ig-induced cell death
appeared to be astrocyte specific. When we performed
the same experiments with genetically labeled oligoden-
drocytes (Plp:CreER3ROSA:STOP-TdTomato), we
observed no overt loss of fluorescence during a 3-hour
imaging period, even though some oligodendrocyte
somata assumed a more rounded shape (mean survival of
oligodendrocytes6 SEM after NMO1 application at
150 lg/ml after 120 minutes in %: 97.06 3.0, n5 3).
NMO-Related Astrocyte Toxicity Is AQP4
Specific and Complement Dependent
To further elucidate the characteristics of NMO-related
astrocyte toxicity in our model, we selectively depleted
AQP4-Ig from one NMO sample (plasma sample
NMO1) using an AQP4-preabsorption column, which
abolished astrocyte damage (Fig 3C). A preabsorption
column without AQP4 antigen had no effect (mean
astrocyte death6 SEM in %: 0.76 0.5, n5 5 vs
78.16 2.1, n5 3 after preabsorption with and without
AQP4 on column, respectively; 360 minutes, Ig adjusted
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to 300 lg/ml in both conditions). Complement inactiva-
tion (i.e., heat treatment of the HD serum added with
the patient samples) also abrogated astrocyte toxicity (Fig
3C, mean astrocyte death6 SEM in %: 0.06 0.0, n5 2;
360 minutes), confirming that AQP4-Ig-mediated astro-
cyte toxicity is a two-component system requiring
AQP4-Ig and complement.16,36 To elucidate which com-
plement activation pathway mediates the observed astro-
cyte damage, we used (1) C1q-depleted complement, (2)
C1q factor alone, and (3) C1q-reconstituted complement
in the presence of AQP4-Ig-containing NMO samples.
We found that whereas C1q depletion alone protected
astrocytes, toxicity was re-established by C1q-
reconstitution (Fig 3D; C1q depletion: 1.86 1.0, n5 3;
C1q alone: 0.06 0.0, n5 3; C1q reconstitution:
87.56 5.0, n5 3; 180 minutes; all values mean6 SEM).
This implies that our model depends on the classical
complement pathway.
To rule out the possibility that the observed effect
was influenced by other antibodies or non-specific factors
present in patient samples, we took advantage of the
recombinant AQP4-specific antibody 7-5-53 (r-AQP4-
IgG), which was generated from a clonotypic plasma
blast present in the CSF of an NMO patient.9 When
combined with a human complement source, a low con-
centration of r-AQP4-IgG (1.5 mg/ml) induced robust
astrocyte pathology (Fig 3E,F; mean survival of astrocy-
tes6 SEM after 120 minutes in %: 44.96 8.5 vs
100.06 0.0 for r-AQP4-IgG vs r-ctrl-IgG, respectively;
n5 3 in both conditions).
NMO-Related Astrocyte Toxicity Leads to
Axonal Pathology
Our in vivo model provides a unique opportunity to
investigate whether NMO-related astrocyte toxicity
affects surrounding axons, given that axon damage can
be followed by two-photon imaging in great detail.21,22
We used combinatorial transgenic labeling of astrocytes
and axons (Aldh1l1:GFP3Thy1:OFP double transgenic
mice) and followed changes in axons for up to 6 hours
after application of NMO samples (Figs 2A and 4A,
Supplementary Video 3). With this labeling, we observed
widespread secondary axon damage in the form of pro-
gressive swellings, which formed along the length of
many axons starting at 100–120 minutes after NMO
sample application until the end of our 6-hour observa-
tion period (i.e., well beyond the time during which we
applied NMO samples, which was discontinued after 90
minutes). This axon pathology was not the consequence
of phototoxicity, given that the same percentage of swol-
len axons was noted, whether or not a time-lapse series
was acquired (Fig 4B). Axonal swellings occurred after
astrocyte loss was well advanced, and the percentage of
swollen axons corresponded to the AQP4-Ig titer and
hence the degree of astrocyte loss (Fig 4C–E; cf. Fig 3A).
After application of control sera, even at high concentra-
tions, no change of axonal morphology could be
observed (Fig 4A,C; mean percentage of axonal swel-
lings6 SEM after 360 minutes: NMO1, 34.36 2.1;
NMO2, 66.56 4.1; NMO3, 21.16 7.2 vs with ctrl1,
2.36 2.4; ctrl2, 0.06 0.0, ctrl3, 1.56 1.3; n5 3 for all
conditions; 150 lg/ml IgG for NMO, 300 lg/ml for ctrl
samples). Notably, we did not observe axon fragmenta-
tion, which we previously demonstrated in other models
of autoimmunity21 or after blunt trauma.22 Indeed, even
after prolonged exposure to AQP4-Ig (NMO1) and HD
for 8 hours (mean percentage astrocyte death6 SEM:
98.86 0.6; mean percentage of axonal swellings6 SEM:
65.76 6.7; n5 3), axons remained apparently continu-
ous (Supplementary Video 4). Inactivation of the com-
plement source or AQP4-Ig depletion from NMO
samples abolished the effect on axons, suggesting that
axonal pathology depends on AQP4-mediated astrocyte
toxicity (Fig 4F; complement inactivation: 0.06 0.0,
n5 2; AQP4-immunoglobulin depletion: 0.06 0.0,
n5 3 vs. preabsorption column without AQP4-antigen:
32.86 4.5, n5 3; all values mean6 s.e.m.). Performing
the same experiments with recombinant AQP4-
antibodies confirmed that r-AQP4-IgG in the presence
of complement is sufficient to induce the observed sec-
ondary axonal changes with a similar relation to astrocyte
damage as observed with AQP4-Ig-containing samples
(Fig 4G; axon swellings in %: r-AQP4-IgG: 46.76 6.3
vs r-ctrl-IgG 0.06 0.0; n5 3 for each condition; all val-
ues mean6 SEM).
Discussion
Here, we use in vivo spinal imaging to reveal the tempo-
ral progression of NMO-related spinal cord pathology
induced by AQP4-Ig and provide new insights into how
antibody-mediated astrocyte damage affects nonastrocytic
structures in the spinal cord. Astrocyte toxicity was spe-
cific to AQP4-Ig, correlated with antibody titer, and was
mediated by the classical complement pathway. Our
study extends previous reports on the potency of human
AQP4-IgG to induce NMO-related astrocyte pathology
in rodents,9,13,14,16 while at the same time providing a
unique dynamic view of astrocyte injury. Moreover, using
combinatorial labeling, we found that after AQP4-Ig-
induced astrocyte loss, axons rapidly developed progres-
sive swellings. Although axonal changes in NMO lesions
in the spinal cord have been described in autopsies11,12,19
and histopathological evidence of axonal injury was
found 12 hours after injection of NMO serum in mouse
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brain,16 to our knowledge, this is the first study to
directly monitor the development of acute (on the order
of hours) axonal pathology in an experimental NMO-
related animal model. Notably, axon damage in this
NMO-related model showed some unique features. Simi-
lar to experimental autoimmune encephalomyelitis
(EAE), a widely used rodent model of MS, axons
exposed to AQP4-IgG and complement developed early
focal swellings. In EAE, however, swollen axons are often
severed,21 an irreversible form of damage commonly
observed after blunt trauma.22 Such axonal transections
were not evident in our NMO-related model, at least
during the first 8 hours, suggesting that there could be
potential for reversing axonal damage early in an NMO
lesion, as has been observed previously in other models
of neuronal damage.21,22,37,38 In addition to revealing
new aspects of axon injury, our in vivo model also allows
investigating the propagation of injury across the glial-
neuronal network starting from a well-defined initial
lesion to astrocytes. In contrast, in other neuroinflamma-
tory models such as EAE, damage results from a complex
and protracted immune insult involving both the innate
and adaptive immune systems, where cellular and
humoral components operate in parallel to injure multi-
ple CNS targets. In addition, the co-visualizing myelin
and oligodendrocytes with astrocytes and axons in
vivo21,31 will allow us to dissect the temporal sequence
and inter-relatedness of the mechanisms governing NMO
and other autoantibody-mediated CNS pathologies.
What is the mechanism driving the rapid axonal
changes? Based on our experience,21,22,32 use of recombi-
nant reagents, and detailed controls, neither additional
components in human samples, imaging, or transgenic
labeling can account for the axonal swellings (for details,
see Materials and Methods). Although we cannot exclude
a possible direct “by-stander” attack of activated comple-
ment factors or an indirect effect by another cell type,39
the timing, lack of associated pathology, and localization
of the axonal changes make these unlikely, and suggest
that axonal swelling is the consequence of astrocyte loss.
Indeed, this is not entirely surprising,40–42 given that
numerous vital interactions between astrocytes and axons
have been documented43–46: For example, astrocytes are
known to scavenge glutamate,47 and excitotoxicity has
been implicated in axonal pathology during neuroinflam-
mation.48–50 This, together with the well-established role
of excitotoxicity after hypoxia,43,51 warrants future inves-
tigation in our NMO-related model using in vivo real-
time optical techniques,52 calcium sensors,22,53 and selec-
tive pharmacological inhibitors. Alternatively, astrocyte
loss could also reduce metabolic support for axons,46,54–56
impair oxidative defense,40,57–59 or alter ion and water
homeostasis,60 predisposing axons to swelling.61 Optical
monitoring of these injury mechanisms within our novel
NMO model system will provide a powerful means to
understand the processes underlying axon damage that
emerges secondary to astrocyte loss.
Despite many advantages, our NMO-related model
has a number of limitations. For instance, the poor
intrinsic activity of complement and the presence of
inhibitors of the classical activation pathway in mice62
require the use of human complement with NMO sam-
ples similar to previous experimental models.9,13,15,16
Whereas we could control for this additional cause of
variability by dissociating the source of AQP4-Ig and of
human complement, natural NMO lesions would use
endogenous complement and hence may have different
kinetics or a distinct spectrum of injury than observed in
our model. Similarly, the direct application of AQP4-Ig
onto a large area of exposed pial surface does not match
the widely assumed primary entry route of serum AQP4-
Ig by a disrupted BBB.5 Nevertheless, the concentration
of serum antibodies that we applied to the spinal cord is
not outside the range of levels found in NMO patients,
especially during relapses.23 Moreover, plasma blasts and
plasma cells can be present in the CSF of NMO patients
and locally release AQP4-Ig,9,63 suggesting that even in
this respect our approach is compatible with some of the
access routes of AQP4-Ig in human NMO.
In conclusion, we report here that human NMO-
derived AQP4-Ig applied to the spinal cord in vivo can
reproduce important features of NMO lesion formation,
which can be monitored by in vivo imaging. Our results
confirm that astrocyte loss appears to be the primary
event of AQP4-Ig-induced lesion formation and rapidly
results in axonal pathology. Our new approach can shed
light on the interdependence of astrocyte health and
axon survival in white matter tracts and potentially
define a window of opportunity for neuroprotective
interventions in NMO.
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